2-((tert-Butoxycarbonyl)amino)-3-(dimethylamino)propanoic acid, 95%, 1g

5-Bromo-1-fluoro-2,3-dimethylbenzene, 98%, 250mg

(r)-1-(6-Methylpyridin-2-yl)ethanol, 98%, 100mg

2-(5-Chloro-2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 1g

2-isobutyl-1H-imidazole, 95.0%, 250mg

5-Bromo-4-iodopyridin-3-amine, 97%, 250mg

Ethyl 3-Bromo-5-chloroimidazo[1,2-a]pyridine-2-carboxylate, 97.0%, 1g

CLARITHROMYCIN, 97%, 1g

Diéthanolamine, min 99 %, pour la synthèse, 2,5 l, emballage plastique.

Oxalate dipotassique monohydraté, min 98%, ultra pur, 500 g, emballage plastique.

N-(2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, 95+%, 50mg

(S)-Amino-(4-hydroxyphenyl)acetic acid, 95.0%, 100g

3-Aminomethyl-1-N-Cbz-piperidine, 95.0%, 10g